Do you feel like you have passed your peak? While men do not experience an abrupt decline in sex hormones like women do, many men start to experience bothersome symptoms as they get older, or gain body weight (regardless of age).

The Aging Males' Symptoms scale (AMS) is the most commonly used scale worldwide to measure health-related quality of life and symptoms in aging males.5 It is a self-administered questionnaire that will help you:6

1) Assess symptoms of aging.
2) Evaluate the severity of your symptoms over time.
3) Measure changes in symptoms before and after testosterone therapy.

Don't forget to print out your results and take them to your doctor on your next visit.

The AMS questionnaire itself (or any other questionnaire) does not constitute a test or diagnosis of hypogonadism (also known as testosterone deficiency). A diagnosis of hypogonadism is based on symptoms that are indicative of testosterone deficiency (the AMS questionnaire can be used for symptom evaluation), combined with low testosterone levels as detected by mandatory blood testing.1-4

References

  • Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. 2016 EAU Guidelines on Male Hypogonadism, available at http://uroweb.org/wp-content/uploads/EAU-Guidelines-MaleHypogonadism-2016.pdf (accessed January 11, 2017). Return to content
  • Dean JD, McMahon CG, Guay AT, et al. The International Society for Sexual Medicine’s Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. The journal of sexual medicine. 2015;12(8):1660-1686 Return to content
  • Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. Appendix available at: http://www.cmaj.ca/content/ suppl/2015/10/26/cmaj.150033.DC1/15-0033-1-at.pdf (accessed Jan 10, 2016). CMAJ. 2015;187(18):1369-1377. Return to content
  • Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2010;95(6):2536 - 2559. Return to content
  • Heinemann LA, Saad F, Zimmermann T, et al. The Aging Males’ Symptoms (AMS) scale: update and compilation of international versions. Health and quality of life outcomes. 2003;1:15. Return to content
  • Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel. C. A new ‘Aging Male’s Symptoms’ (AMS) rating scale. The aging male : the official journal of the International Society for the Study of the Aging Male. 1999;2:105–114. Return to content
  • Daig I, Heinemann LA, Kim S, et al. The Aging Males’ Symptoms (AMS) scale: review of its methodological characteristics. Health and quality of life outcomes. 2003;1:77 Return to content
  • Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. The aging male : the official journal of the International Society for the Study of the Aging Male. 2015;18(1):5-15 Return to content
  • Dean JD, McMahon CG, Guay AT, et al. The International Society for Sexual Medicine’s Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. The journal of sexual medicine. 2015;12(8):1660-1686. Return to content
  • Morales A, Bebb RA, Manjoo P, et al. Multidisciplinary Canadian Clinical Practice Guideline on the Diagnosis and Management of Testosterone Deficiency Syndrome in Adult Males. CMAJ. 2015. Return to content
  • Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 2006;91(11):4335 - 4343. Return to content
  • Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. The journal of sexual medicine. 2008;5(4):998 - 1012. Return to content
  • Collier CP, Morales A, Clark A, Lam M, Wynne-Edwards K, Black A. The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. J. Urol. 2010;183(6):2294 - 2299. Return to content
  • Morgentaler A, Khera M, Maggi M, Zitzmann M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. The journal of sexual medicine. 2014;11(7):1636-1645. Return to content
  • Heinemann LA, Moore C, Dinger JC, Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS scale. Health and quality of life outcomes. 2006;4:23. Return to content
  • Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur. Urol. 2004;46(1):80-87. Return to content